17 Oct SHINE Technologies Collaborates with University of Wisconsin-Madison and WARF Therapeutics to Create Promising New Treatments for Kidney and Prostate Cancers
Pre-clinical research results show that WARF Therapeutics’ WT-7695 radiopharmaceutical, which uses SHINE’s Ilumira, achieved 100% survival in a model of kidney cancer . ART-101, a novel prostate cancer treatment developed at the Advanced Radiotheranostics Lab using SHINE’s Ilumira, demonstrates superior efficacy compared to current therapies
JANESVILLE, Wis., Oct. 17, 2024 – SHINE Technologies, a next-generation fusion company, and WARF Therapeutics, a drug discovery program by the Wisconsin Alumni Research Foundation (WARF), today announced promising pre-clinical research results from collaborative efforts with Advanced Radiotheranostics Lab at the University of Wisconsin-Madison. The studies showed that WT-7695 and ART-101 – treatments that leverage SHINE’s non-carrier added lutetium-177 (Lu-177) chloride, Ilumira – have the potential to increase life span and be more effective in treating kidney and prostate cancer, respectively.
This groundbreaking research stems from a collaboration between the Advanced Radiotheranostic Lab, led by Dr. Reinier Hernandez at the University of Wisconsin-Madison, WARF Therapeutics, and SHINE Technologies. WARF Therapeutics has heavily invested to accelerate the development of theranostic radiopharmaceutical programs at UW-Madison, like WT-7695 and ART-101, while SHINE Technologies provides the high-quality n.c.a. lutetium-177 integral to this innovative cancer treatment approach.
When paired with innovative cancer-seeking radiopharmaceutical agents that precisely target tumors and metastases, Lu-177 delivers a potent dose of radiation to kill cancer cells while minimizing harm to healthy tissue. Research has shown that radiopharmaceuticals have the potential to reduce the risk of side effects from treatment compared to other cancer therapies.